Cerus (CERS)
Cerus on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus.
17.6M
Short interest
settlement 2026-09-30
8.0
Days to cover
-8.5 days vs prior
40.4%
Short share of volume
2026-10-09
541
Fails to deliver
settlement 2026-08-26
Thu 5 Nov
Next earnings
estimated date
-$142K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in CERS is 17,580,423 shares, down 137,293 shares over the last month. Over the last 48 readings it ranged from 5,172,543 shares (15 October 2025) to 19,696,885 shares (15 June 2026). At the reported average volume of 2.2M shares a day that is 8.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cers" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 17,580,423 | -2.3% | 2,188,865 | 8.03 |
| 2026-09-15 | 17,994,821 | +1.6% | 1,085,581 | 16.58 |
| 2026-08-31 | 17,717,716 | +2.2% | 1,769,079 | 10.02 |
| 2026-08-14 | 17,330,786 | +15.8% | 3,417,338 | 5.07 |
| 2026-07-31 | 14,960,162 | +9.3% | 2,619,098 | 5.71 |
| 2026-07-15 | 13,688,689 | +7.5% | 2,487,355 | 5.50 |
| 2026-06-30 | 12,738,396 | -35.3% | 3,078,951 | 4.14 |
| 2026-06-15 | 19,696,885 | +82.9% | 2,320,242 | 8.49 |
| 2026-05-29 | 10,766,701 | -41.9% | 2,541,848 | 4.24 |
| 2026-05-15 | 18,522,745 | +64.3% | 4,628,884 | 4.00 |
| 2026-04-30 | 11,273,044 | +0.6% | 1,073,047 | 10.51 |
| 2026-04-15 | 11,204,876 | +0.8% | 899,630 | 12.45 |
| 2026-03-31 | 11,119,137 | +5.8% | 1,764,992 | 6.30 |
| 2026-03-13 | 10,511,205 | +35.1% | 2,914,492 | 3.61 |
| 2026-02-27 | 7,781,596 | -0.5% | 1,368,390 | 5.69 |
| 2026-02-13 | 7,818,308 | +16.3% | 976,624 | 8.01 |
| 2026-01-30 | 6,725,116 | -5.9% | 1,133,279 | 5.93 |
| 2026-01-15 | 7,143,959 | +6.4% | 1,972,016 | 3.62 |
| 2025-12-31 | 6,714,909 | +7.6% | 1,383,526 | 4.85 |
| 2025-12-15 | 6,239,300 | +6.9% | 1,732,942 | 3.60 |
| 2025-11-28 | 5,838,160 | +2.0% | 1,309,915 | 4.46 |
| 2025-11-14 | 5,720,796 | +9.6% | 1,393,250 | 4.11 |
| 2025-10-31 | 5,222,244 | +1.0% | 1,105,655 | 4.72 |
| 2025-10-15 | 5,172,543 | -16.5% | 1,325,656 | 3.90 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of CERS volume is 40.4%, down 13.9 points over the last five sessions. Over the last 30 readings it ranged from 29.6% (17 September 2026) to 75.4% (4 September 2026). The latest reading is 8.8 points below the 30-session average of 49.2%, on 274K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 111K | 274K | 40.4% | 59 |
| 2026-10-08 | 326K | 792K | 41.1% | 3,560 |
| 2026-10-07 | 180K | 289K | 62.1% | 222 |
| 2026-10-06 | 369K | 556K | 66.4% | 547 |
| 2026-10-05 | 321K | 673K | 47.7% | 1,179 |
| 2026-10-02 | 333K | 614K | 54.3% | 883 |
| 2026-10-01 | 273K | 661K | 41.3% | 7,030 |
| 2026-09-30 | 288K | 609K | 47.3% | 30 |
| 2026-09-29 | 393K | 643K | 61.0% | 40 |
| 2026-09-28 | 216K | 529K | 40.9% | 2,226 |
| 2026-09-25 | 391K | 989K | 39.5% | 400 |
| 2026-09-24 | 233K | 730K | 31.9% | 506 |
| 2026-09-23 | 294K | 551K | 53.4% | 495 |
| 2026-09-22 | 644K | 1.9M | 34.2% | 3,396 |
| 2026-09-21 | 391K | 734K | 53.3% | 399 |
| 2026-09-18 | 367K | 943K | 38.9% | 8,987 |
| 2026-09-17 | 351K | 1.2M | 29.6% | 280 |
| 2026-09-16 | 203K | 423K | 47.9% | 0 |
| 2026-09-15 | 135K | 340K | 39.6% | 100 |
| 2026-09-14 | 168K | 470K | 35.7% | 2,467 |
| 2026-09-11 | 320K | 645K | 49.6% | 1,740 |
| 2026-09-10 | 217K | 308K | 70.5% | 142 |
| 2026-09-09 | 207K | 335K | 61.7% | 555 |
| 2026-09-08 | 151K | 280K | 54.1% | 4,068 |
| 2026-09-04 | 343K | 455K | 75.4% | 124 |
| 2026-09-03 | 156K | 328K | 47.5% | 1,126 |
| 2026-09-02 | 325K | 705K | 46.1% | 48 |
| 2026-09-01 | 212K | 388K | 54.5% | 11 |
| 2026-08-31 | 229K | 387K | 59.2% | 0 |
| 2026-08-28 | 353K | 686K | 51.5% | 136 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 26 August 2026, the fails-to-deliver balance in CERS is 541 shares, down 2,031 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (21 October 2025) to 152,260 shares (15 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-26 | 541 | $2.72 | $1K |
| 2026-08-24 | 2,572 | $2.81 | $7K |
| 2026-08-21 | 227 | $2.79 | $633 |
| 2026-08-11 | 1,082 | $2.52 | $3K |
| 2026-08-10 | 28 | $2.35 | $66 |
| 2026-08-06 | 776 | $2.27 | $2K |
| 2026-07-13 | 55,434 | $3.12 | $173K |
| 2026-07-06 | 11,937 | $3.16 | $38K |
| 2026-07-02 | 663 | $3.00 | $2K |
| 2026-06-26 | 5 | $2.86 | $14 |
| 2026-06-02 | 14,151 | $2.84 | $40K |
| 2026-05-19 | 10,191 | $2.43 | $25K |
| 2026-05-15 | 152,260 | $2.51 | $382K |
| 2026-05-14 | 9,997 | $2.60 | $26K |
| 2026-05-11 | 376 | $2.61 | $981 |
| 2026-05-08 | 1,921 | $2.61 | $5K |
| 2026-05-07 | 15,423 | $2.59 | $40K |
| 2026-05-01 | 242 | $2.03 | $491 |
| 2026-04-16 | 1,110 | $2.02 | $2K |
| 2026-04-15 | 1,355 | $2.01 | $3K |
| 2026-03-20 | 5,000 | $1.76 | $9K |
| 2026-03-03 | 21,851 | $2.53 | $55K |
| 2026-02-06 | 350 | $2.14 | $749 |
| 2026-02-03 | 1,377 | $2.32 | $3K |
| 2026-02-02 | 1,377 | $2.33 | $3K |
| 2026-01-16 | 60,000 | $2.74 | $164K |
| 2026-01-15 | 2,612 | $2.74 | $7K |
| 2025-11-17 | 4,840 | $1.62 | $8K |
| 2025-11-07 | 200 | $1.41 | $282 |
| 2025-10-21 | 3 | $1.63 | $5 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at CERS reported 2 open-market sells worth $142K in the last 90 days and no open-market buys. Latest filing: Jensen Chrystal (Chief Legal Officer) on 2026-08-17.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Jensen Chrystal | Chief Legal Officer | Sell | 30K | $2.98 | $90K | 937K |
| 2026-07-16 | Jayaraman Vivek K | Chief Executive Officer | Sell | 17K | $3.16 | $53K | 2.2M |
| 2026-07-01 | Jayaraman Vivek K | Chief Operating Officer | Grant | 555K | $0.00 | $0 | 2.2M |
| 2026-06-30 | Jayaraman Vivek K | Chief Operating Officer | Sell | 42K | $2.94 | $125K | 1.7M |
| 2026-06-30 | Jayaraman Vivek K | Chief Operating Officer | Grant | 80K | $0.00 | $0 | 1.7M |
| 2026-06-30 | Jensen Chrystal | Chief Legal Officer | Sell | 24K | $2.94 | $72K | 967K |
| 2026-06-30 | Jensen Chrystal | Chief Legal Officer | Grant | 55K | $0.00 | $0 | 991K |
| 2026-06-30 | Green Kevin Dennis | Chief Financial Officer | Sell | 34K | $2.94 | $99K | 1.1M |
| 2026-06-30 | Green Kevin Dennis | Chief Financial Officer | Grant | 64K | $0.00 | $0 | 1.1M |
| 2026-06-30 | Greenman William Mariner | President and CEO | Sell | 102K | $2.94 | $300K | 5.1M |
| 2026-06-30 | Greenman William Mariner | President and CEO | Grant | 193K | $0.00 | $0 | 5.2M |
| 2026-06-09 | BJERKHOLT ERIC | Director | Sell | 20K | $2.60 | $53K | 262K |
| 2026-06-02 | Lucena Ann | Director | Grant | 60K | $0.00 | $0 | 232K |
| 2026-06-02 | NACHTSHEIM JAMI K | Director | Grant | 60K | $0.00 | $0 | 268K |
| 2026-06-02 | Witney Frank | Director | Grant | 60K | $0.00 | $0 | 340K |
| 2026-06-02 | Gregory Dean A. | Director | Grant | 60K | $0.00 | $0 | 147K |
| 2026-06-02 | Shan Hua | Director | Grant | 60K | $0.00 | $0 | 192K |
| 2026-06-02 | BJERKHOLT ERIC | Director | Grant | 60K | $0.00 | $0 | 282K |
| 2026-05-29 | Jayaraman Vivek K | Chief Operating Officer | Sell | 17K | $3.00 | $50K | 1.7M |
| 2026-05-01 | Jayaraman Vivek K | Chief Operating Officer | Sell | 17K | $3.00 | $50K | 1.7M |
| 2026-04-01 | Jensen Chrystal | Chief Legal Officer | Grant | 200K | $0.00 | $0 | 1.1M |
| 2026-04-01 | Green Kevin Dennis | Chief Financial Officer | Grant | 200K | $0.00 | $0 | 1.2M |
| 2026-03-12 | Jayaraman Vivek K | Chief Operating Officer | Sell | 165K | $1.66 | $274K | 1.7M |
| 2026-03-12 | Green Kevin Dennis | Chief Financial Officer | Sell | 128K | $1.66 | $211K | 1.0M |
| 2026-03-12 | Greenman William Mariner | President and CEO | Sell | 448K | $1.66 | $742K | 5.0M |
| 2026-03-12 | Benjamin Richard J | Chief Medical Officer | Sell | 102K | $1.66 | $169K | 777K |
| 2026-03-09 | Benjamin Richard J | Chief Medical Officer | Sell | 40K | $1.88 | $76K | 879K |
| 2026-03-09 | Benjamin Richard J | Chief Medical Officer | Sell | 40K | $1.88 | $76K | 879K |
| 2026-03-06 | Benjamin Richard J | Chief Medical Officer | Sell | 24K | $2.01 | $49K | 920K |
| 2026-03-06 | Jayaraman Vivek K | Chief Operating Officer | Sell | 34K | $2.01 | $68K | 1.9M |
| 2026-03-06 | Jensen Chrystal | Chief Legal Officer | Sell | 31K | $2.01 | $62K | 1.1M |
| 2026-03-06 | Green Kevin Dennis | Chief Financial Officer | Sell | 28K | $2.01 | $56K | 1.2M |
| 2026-03-06 | Greenman William Mariner | President and CEO | Sell | 78K | $2.01 | $157K | 5.4M |
| 2026-03-06 | Benjamin Richard J | Chief Medical Officer | Sell | 24K | $2.01 | $49K | 920K |
| 2026-03-05 | Benjamin Richard J | Chief Medical Officer | Sell | 61K | $2.06 | $126K | 944K |
| 2026-03-05 | Jayaraman Vivek K | Chief Operating Officer | Grant | 80K | $0.00 | $0 | 1.9M |
| 2026-03-05 | Jensen Chrystal | Chief Legal Officer | Grant | 55K | $0.00 | $0 | 1.1M |
| 2026-03-05 | Green Kevin Dennis | Chief Financial Officer | Sell | 55K | $2.06 | $114K | 1.2M |
| 2026-03-05 | Green Kevin Dennis | Chief Financial Officer | Grant | 64K | $0.00 | $0 | 1.3M |
| 2026-03-05 | Greenman William Mariner | President and CEO | Grant | 193K | $0.00 | $0 | 5.5M |
| 2026-03-05 | Benjamin Richard J | Chief Medical Officer | Sell | 61K | $2.06 | $126K | 944K |
| 2026-03-05 | Benjamin Richard J | Chief Medical Officer | Grant | 55K | $0.00 | $0 | 1.0M |
| 2026-03-02 | Jayaraman Vivek K | Chief Operating Officer | Grant | 420K | $0.00 | $0 | 1.9M |
| 2026-03-02 | Jensen Chrystal | Chief Legal Officer | Grant | 300K | $0.00 | $0 | 1.0M |
| 2026-03-02 | Green Kevin Dennis | Chief Financial Officer | Grant | 300K | $0.00 | $0 | 1.2M |
| 2026-03-02 | Greenman William Mariner | President and CEO | Grant | 1.2M | $0.00 | $0 | 5.3M |
| 2026-03-02 | Benjamin Richard J | Chief Medical Officer | Grant | 264K | $0.00 | $0 | 950K |
| 2025-11-24 | Jensen Chrystal | Chief Legal Officer | Sell | 55K | $1.70 | $94K | 728K |
| 2025-08-25 | Gregory Dean A. | Director | Buy | 25K | $1.25 | $31K | 87K |
| 2025-06-03 | BJERKHOLT ERIC | Director | Grant | 60K | $0.00 | $0 | 222K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for CERS worth $920K at the prices reported; 2 in the last 90 days worth $142K. Latest: CHRYSTAL NIKOLE JENSEN filed on 2026-08-17 to sell 30,000 shares ($90K) from 2026-08-17.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-17 | CHRYSTAL NIKOLE JENSENOfficer | 30K | $90K | 0.015% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-16 | VIVEK K JAYARAMANOfficer | 17K | $53K | 0.008% | 2026-07-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-09 | ERIC BJERKHOLTDirector | 20K | $53K | 0.010% | 2026-06-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-29 | VIVEK K JAYARAMANOfficer | 17K | $50K | 0.008% | 2026-05-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | VIVEK K JAYARAMANOfficer | 17K | $50K | 0.008% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | RICHARD J BENJAMINOfficer | 76K | $215K | 0.038% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-09 | RICHARD J BENJAMINOfficer | 40K | $76K | 0.021% | 2026-03-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-05 | KEVIN D GREENOfficer | 55K | $114K | 0.029% | 2026-03-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-05 | RICHARD J BENJAMINOfficer | 61K | $126K | 0.032% | 2026-03-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-24 | CHRYSTAL NIKOLE JENSENOfficer | 55K | $94K | 0.029% | 2025-11-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of CERS in their latest filing, all on Schedule 13G (passive). The largest reported stake is ARK Investment Management LLC at 8.9% of the class (17,932,099 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 13 | Baker Bros. Advisors LPinvestment adviser, partnership | 6.4M | 3.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 13 | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 6.4M | 3.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 13 | Julian C. Bakerparent holding company, individual | 6.4M | 3.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 13 | Felix J. Bakerparent holding company, individual | 6.4M | 3.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 11 | ARK Investment Management LLCinvestment adviser | 17.9M | 8.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 11 | Catherine D. Woodparent holding company, individual | 17.9M | 8.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus Capital Master Fund, L.P.non-US institution | 2.5M | 1.2% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus Capital, LLCother entity | 2.5M | 1.2% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus Capital Group, LLCother entity | 2.5M | 1.2% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus Capital Management, L.P.partnership | 2.5M | 1.2% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Soleus GP, LLCother entity | 2.5M | 1.2% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Guy Levyindividual | 2.5M | 1.2% | 2026-06-30 |
| 2026-03-26 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding CERS at their latest 13F. JSON8 of the 30 tracked managers held CERS at their latest 13F, $89.1M in total at quarter-end prices. ARK Investment Management is the largest at $52.4M (0.3% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| ARK Investment Management | 2026-06-30 | 17.9M | $52.4M | 0.34% | -1.2M |
| D. E. Shaw & Co. | 2026-06-30 | 5.5M | $16.0M | 0.01% | +1.8M |
| Two Sigma Investments | 2026-06-30 | 3.5M | $10.2M | 0.01% | +740K |
| AQR Capital Management | 2026-06-30 | 1.9M | $5.5M | 0.00% | -235K |
| Citadel Advisors | 2026-06-30 | 737K | $2.2M | 0.00% | new |
| Renaissance Technologies | 2026-06-30 | 672K | $2.0M | 0.00% | +93K |
| Point72 Asset Management | 2026-06-30 | 228K | $666K | 0.00% | new |
| Millennium Management | 2026-06-30 | 108K | $317K | 0.00% | -322K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Cerus reported revenue of $57.4M, up 9.5% from the same quarter a year earlier, and net loss of $2.9M (-0.01 diluted EPS). In FY 2025 it generated $4.8M of operating cash flow.
- Cash
- $18.0M
- Equity
- $70.0M
- Total assets
- $205.2M
- Shares outstanding
- 201,524,898
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $57.4M | -$2.9M | -5.1% | -0.01 |
| Q1 FY 2026 | 2026-03-31 | $53.7M | -$1.6M | -3.1% | -0.01 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$2.2M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$19K | n/a | 0.00 |
| Q2 FY 2025 | 2025-06-30 | $52.4M | -$5.7M | -10.9% | -0.03 |
| Q1 FY 2025 | 2025-03-31 | $43.2M | -$7.7M | -17.8% | -0.04 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$2.5M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$2.9M | n/a | -0.02 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $233.8M | -$15.6M | $4.8M | $3.7M | n/a | n/a |
| FY 2024 | 2024-12-31 | $201.3M | -$20.9M | $11.4M | $2.8M | n/a | n/a |
| FY 2023 | 2023-12-31 | $186.8M | -$37.5M | -$43.2M | $4.6M | n/a | n/a |
| FY 2022 | 2022-12-31 | $188.3M | -$42.8M | -$25.6M | $2.0M | n/a | n/a |
| FY 2021 | 2021-12-31 | $159.5M | -$54.4M | -$33.9M | $910K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-16 from the cover page.
What this page is
Cerus in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Cerus (CERS), SEC CIK 1020214, listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-26.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-17.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-17.JSON and CSV
- Company record
- EDGAR filing index for CIK 1020214Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
- BSXBoston Scientific
- TNDMTandem Diabetes Care
- DXCMDexCom
- PENPenumbra
- INSPInspire Medical Systems
- SIBNSi-Bone
- LMATLemaitre Vascular
- MMM3M
- NVCRNovoCure
- RMDResMed
- SYKStryker
- GKOSGlaukos
- IRTCiRhythm Holdings
- ICUIIcu Medical
- ATECAlphatec Holdings
- IARTIntegra Lifesciences Holdings
- AORTArtivion
- PODDInsulet
- BDXBecton, Dickinson
- IRMDIradimed
- SIShoulder Innovations
- ATRCAtriCure
- TMCITreace Medical Concepts
- UFPTUfp Technologies
Datasets
Frequently Asked Questions
How much of CERS is sold short?
What is CERS's daily short volume?
Does CERS have fails to deliver?
Are CERS insiders buying or selling?
Have CERS insiders filed to sell?
Who owns 5% or more of CERS?
What did CERS report last quarter?
Which tracked 13F managers own CERS?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.